Covid-19 Pandemic
 Here’s the latest news from the global pandemic. Germany cushions Covid blow by weaning itself off exportsChina broker pressured H.K. staff on virus test, union saysJPMorgan tells investors to prepare for rising odds of Trump win Deciding who to test for Covid isn’t so easy Who ought to be tested for Covid-19? That question has loomed over America’s response to the coronavirus from the earliest days, when arriving travelers from infection hot spots weren’t screened unless they had symptoms. It’s looming still. One answer is: pretty much everyone, as often as possible. Vulnerable nursing home residents, anyone on a college campus, bus drivers and factory workers. Ubiquitous testing, the argument goes, can detect the virus’s silent spread and allow carriers to isolate before they pass it on.  Discarded rapid Covid-19 test equipment in a bio hazard waste bin at San Francisco International Airport. Photographer: David Paul Morris/Bloomberg But we don’t have enough supply to test everyone all the time. So health officials, doctors, employers and schools must decide how to allocate the tests we do have. Those decisions must balance the public health need for surveillance – picking up unknown, invisible infections – with diagnostic tests needed to tell whether a sick person’s illness is Covid or not. Right now, the decisions often seem more random than based on clear evidence for when a test is warranted. Some nursing home residents are tested weekly, a vigilant surveillance regime. But because of bottlenecks at labs, they sometimes don’t have the results back before it’s time to take a new test. Some college campuses are testing students weekly, while others select a sample group or test those who show symptoms. The U.S. Centers for Disease Control and Prevention escalated the confusion last week when it changed a guideline on its website to suggest that people who have close contact with someone who tested positive for Covid-19 may not need to get tested themselves. The move was widely panned as political and denounced by doctors and infectious-disease experts. A new, low-cost test from Abbott Laboratories is set to boost the supply this fall, which could ease the trade-off between surveillance and diagnostic testing. But until the virus in the U.S. is tamed to much lower levels, or testing capacity exponentially increases, the question of who, when and how often to test won’t be easy to answer. –John Tozzi Latest podcast What Sweden Got Right—and Wrong Its strategy has been controversial. Sweden’s Covid-19 death rate is considerably higher than in many other countries. But the pace of new infections and deaths has slowed markedly since June. Stockholm-based reporter Niclas Rolander has the details.  Sponsored Content by Siemens America’s factories, power plants, transportation and hospitals all need technology and our technology is only as powerful as the people deploying and maintaining it. Keeping America moving takes more than technology alone. It takes a human touch. Siemens Ingenuity for life. What you should read Trade Rebound Seen Faster Than Post-Lehman Revival in shipping volumes hints at V-shaped recovery, institute says. India’s Gen Z Risks Being Left Out of Formal Jobs Pandemic is making it even harder for the youngest workers to earn a living. Russia Passes 1 Million Cases as Schools Open Second waves in Europe spark concern country could see infections spike. People Flee for Florida, Texas as Mobility Surges Real-estate meccas aren’t the same as New Yorkers move to Sun Belt. Back to School: Britain Is Counting On You Returning kids to classroom is an unavoidable gamble for Boris Johnson. Know someone else who would like this newsletter? Have them sign up here. Have any questions, concerns, or news tips on Covid-19 news? Get in touch or help us cover the story. Like this newsletter? Subscribe for unlimited access to trusted, data-based journalism in 120 countries around the world and gain expert analysis from exclusive daily newsletters, The Bloomberg Open and The Bloomberg Close. Follow Us Get the newsletter You received this message because you are subscribed to Bloomberg’s Coronavirus Daily newsletter. Unsubscribe | Bloomberg.com | Contact Us Bloomberg L.P. 731 Lexington, New York, NY, 10022 |
PreviousCovid-19 Pandemic